A quantum dot probe conjugated with Aβ antibody for molecular imaging of Alzheimer's disease in a mouse model

Cellular and Molecular Neurobiology

Volumn 33, Issue 6, 2013, Pages 759-765

  Feng, Li ^a   Long, Hong Yu ^a   Liu, Ren Kai ^b   Sun, Dan Ni ^a   Liu, Chao ^a   Long, Li Li ^a   Li, Yi ^a   Chen, Si ^a   Xiao, Bo ^a  

^a CENTRAL SOUTH UNIVERSITY   (China)

^b Shenzhen Nanshan People s Hospital and the 6th Affiliated Hospital of Shenzhen University Medical School   (China)

Author keywords

Amyloid; Alzheimer's disease; Molecular imaging; Quantum dots

Indexed keywords

AMYLOID BETA PROTEIN ANTIBODY; AMYLOID BETA PROTEIN[1-42]; AMYLOID PRECURSOR PROTEIN; CADMIUM SELENIDE; QUANTUM DOT; ZINC SULFIDE; AMYLOID BETA PROTEIN; ANTIBODY;

ALZHEIMER DISEASE; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APP GENE; ARTICLE; BRAIN CORTEX; BRAIN TISSUE; CONTROLLED STUDY; CORPUS STRIATUM; DISEASE MODEL; FLUORESCENCE ANALYSIS; FLUORESCENCE MICROSCOPY; GENE; GENE MUTATION; HIPPOCAMPAL CA1 REGION; HIPPOCAMPUS; IMMUNOHISTOCHEMISTRY; IN VIVO STUDY; MALE; MOLECULAR IMAGING; MOLECULAR PROBE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN LOCALIZATION; TRANSGENE; TRANSGENIC MOUSE; ANIMAL; C57BL MOUSE; HUMAN; IMMUNOLOGY; METABOLISM; PATHOLOGY; PROCEDURES; TOXICITY;

MUS; MUS MUSCULUS;

ALZHEIMER DISEASE; AMYLOID BETA-PEPTIDES; ANIMALS; ANTIBODIES; CA1 REGION, HIPPOCAMPAL; DISEASE MODELS, ANIMAL; HUMANS; MALE; MICE; MICE, INBRED C57BL; MICE, TRANSGENIC; MICROSCOPY, FLUORESCENCE; MOLECULAR IMAGING; QUANTUM DOTS;

EID: 84881109913     PISSN: 02724340     EISSN: 15736830     Source Type: Journal    
DOI: 10.1007/s10571-013-9943-6     Document Type: Article

References (24)

1. Ai X, Xu Q, Jones M, Song Q, Ding SY, Ellingson RJ, Himmel M, Rumbles G (2007) Photophysics of (CdSe)ZnS colloidal quantum dots in an aqueous environment stabilized with amino acids and genetically-modified proteins. Photochem Photobiol Sci 6:1027-1033
2. Alivisatos AP (1996) Semiconductor clusters, nanocrystals, and quantum dots. Science 271:933-937
3. Berchtold NC, Cotman CW (1998) Evolution in the conceptualization of dementia and Alzheimer's disease: Greco-Roman period to the 1960s. Neurobiol Aging 19:173-189
4. Bermejo-Pareja F, Antequera D, Vargas T, Molina JA, Carro E (2010) Saliva levels of Abeta1-42 as potential biomarker of Alzheimer's disease: a pilot study. BMC Neurol 10:108
5. Blennow K, Zetterberg H (2009) Use of CSF biomarkers in Alzheimer's disease clinical trials. J Nutr Health Aging 13:358-361
6. Boche D, Denham N, Holmes C, Nicoll JA (2010) Neuropathology after active Abeta42 immunotherapy: implications for Alzheimer's disease pathogenesis. Acta Neuropathol 120:369-384
7. Braak H, Braak E (1997) Frequency of stages of Alzheimer-related lesions in different age categories. Neurobiol Aging 18:351-357
8. Brookmeyer R, Johnson E, Ziegler-Graham K, Arrighi HM (2007) Forecasting the global burden of Alzheimer's disease. Alzheimers Dement 3:186-191
9. Buchhave P, Minthon L, Zetterberg H, Wallin AK, Blennow K, Hansson O (2012) Cerebrospinal fluid levels of β-amyloid 1-42, but not of tau, are fully changed already 5 to 10 years before the onset of Alzheimer dementia. Arch Gen Psychiatry 69:98-106
10. Checler F, Buée L (2009) Fundamental data on the pathologies amyloid and Tau in Alzheimer's disease: which therapeutic perspectives? Ann Pharm Fr 67:136-153
11. Chen Y, Xiong T, Yu L, Zeng S, Luo Q (2005) Whole-body fluorescent optical imaging based on power light emitting diode. Conf Proc IEEE Eng Med Biol Soc 2:1442-1445
12. Chen LD, Liu J, Yu XF, He M, Pei XF, Tang ZY, Wang QQ, Pang DW, Li Y (2008) The biocompatibility of quantum dot probes used for the targeted imaging of hepatocellular carcinoma metastasis. Biomaterials 29:4170-4176
13. Dahan M, Levi S, Luccardini C, Rostaing P, Riveau B, Triller A (2003) Diffusion dynamics of glycine receptors revealed by single quantum dot tracking. Science 302:442-445
14. Feng L, Li S, Xiao B, Chen S, Liu R, Zhang Y (2010) Fluorescence imaging of APP in Alzheimer's disease with quantum dot or Cy3: a comparative study. Zhong Nan Da Xue Xue Bao Yi Xue Ban 35:903-909
15. Gao X, Cui Y, Levenson RM, Chung LW, Nie S (2004) In vivo cancer targeting and imaging with semiconductor quantum dots. Nat Biotechnol 22:969-976
16. Haute Autorité de Santée (2008) Diagnosis and management of Alzheimer's disease and related diseases. Rev Neurol (Paris) 164:754-774
17. Jaiswal JK, Mattoussi H, Mauro JM, Simon SM (2003) Long-term multiple color imaging of live cells using quantum dot bioconjugates. Nat Biotechnol 21:47-51
18. Kasuga K, Tokutake T, Ishikawa A, Uchiyama T, Tokuda T, Onodera O, Nishizawa M, Ikeuchi T (2010) Differential levels of alpha-synuclein, beta-amyloid42 and tau in CSF between patients with dementia with Lewy bodies and Alzheimer's disease. J Neurol Neurosurg Psychiatry 81:608-610
19. Kawas CH, Corrada MM, Brookmeyer R, Morrison A, Resnick SM, Zonderman AB, Arenberg D (2003) Visual memory predicts Alzheimer's disease more than a decade before diagnosis. Neurology 60:1089-1093
20. Kim S, Swaminathan S, Shen L et al (2011) Genome-wide association study of CSF biomarkers Abeta1-42, t-tau, and p-tau181p in the ADNI cohort. Neurology 76:69-79
21. Perneczky R, Kurz A (2008) Diagnosis and therapy of Alzheimer's disease: what's important for the family doctor? MMW Fortschr Med 150:42-45
22. Selkoe DJ (2001) Alzheimer's disease: genes, protein and therapy. Physiol Rev 81:741-766
23. Walling MA, Novak JA (2009) Shepard JR. Quantum dots for live cell and in vivo imaging. Int J Mol Sci 10:441-491
24. Xu G, Yong KT, Roy I, Mahajan SD, Ding H, Schwartz SA, Prasad PN (2008) Bioconjugated quantum rods as targeted probes for efficient transmigration across an in vitro blood-brain barrier. Bioconjug Chem 19:1179-1185